adaptive designsadaptive information designadaptive study designsbiostatisticsclinical trial simulationdropping a treatment armexperimental designFDA critical pathguidance developmentmissing datamultiple endpointsnon-inferioritynon-inferiority trialsphase III clinical trialsquantitative risk/safety assessmentregulatory biostatisticsregulatory evaluationstatistical efficiencystatistical informationsuperiority
Recommendations
- Adaptive designs from the viewpoint of an academic biostatistician
- Methodological developments vs. regulatory requirements
- Challenges in implementing adaptive designs: comments on the viewpoints expressed by regulatory statisticians
- A consultant's perspective on the regulatory hurdles to adaptive trials
- Rejoinder
Cited in
(8)- Editorial -- Adaptive designs: expectations are high
- FDA's critical path initiative: a perspective on contributions of biostatistics
- Adaptive designs from the viewpoint of an academic biostatistician
- Challenges in implementing adaptive designs: comments on the viewpoints expressed by regulatory statisticians
- A consultant's perspective on the regulatory hurdles to adaptive trials
- Methodological developments vs. regulatory requirements
- Rejoinder
- How practical are adaptive designs likely to be for confirmatory trials?
This page was built for publication: Opening the adaptive toolbox
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5122845)